WO2024180371 - SYNTHESIS AND PURIFICATION OF THE ACTIVE PHARMACEUTICAL INGREDIENT OF ANAGRELIDE HYDROCHLORIDE AND ALL ITS INTERMEDIATES
National phase entry is expected:
Publication Number
WO/2024/180371
Publication Date
06.09.2024
International Application No.
PCT/IB2023/051931
International Filing Date
02.03.2023
Title **
[English]
SYNTHESIS AND PURIFICATION OF THE ACTIVE PHARMACEUTICAL INGREDIENT OF ANAGRELIDE HYDROCHLORIDE AND ALL ITS INTERMEDIATES
[French]
SYNTHÈSE ET PURIFICATION DU PRINCIPE PHARMACEUTIQUE ACTIF DE CHLORHYDRATE D'ANAGRÉLIDE ET DE TOUS SES INTERMÉDIAIRES
Applicants **
MOHAMMADI, Ali
No.5, Helal Al., Amir kabir Sou., Jalal Al Ahmad Blv., Ashrafi Esfahani Ave.
Tehran, 1461614141, IR
Inventors
RAMAZANI, Ali
No.32, Ordibehesht St., Hor Ave.,
Zanjan, 4513737567, IR
AGHAHOSSEINI, Hamideh
No.25, Hekmat Al., Boostan Ave.,
Qazvin, 3414656818, IR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 918 | |
| EPO | Filing, Examination | 4891 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 7435 |
Total: 14257 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Anagrelide hydrochloride is a synthetic derivative of benzene used to treat primary thrombocythemia and secondary thrombocytes as well as myeloproliferative disorders. Anagrelide has a unique function, so that it can selectively reduce the number of platelets, without affecting other types of blood cells. In the present invention, all key intermediates and active pharmaceutical ingredients of Anagrelide hydrochloride were synthesized using cheap and available raw materials. In this regard, appropriate, practical and cost-effective methods were used by carefully examining the available synthetic routes to produce all the key intermediates and the active component of Anagrelide. Also, the many and complex stages of separation and purification of products were greatly facilitated by developing simple methods for separation and purification of products, such as the crystallization process or choosing the right combination of washing solvents.[French]
Le chlorhydrate d'anagrelide est un dérivé synthétique de benzène utilisé pour traiter une thrombocytémie primaire et des thrombocytes secondaires ainsi que des troubles myéloprolifératifs. L'anagrélide a une fonction unique, de telle sorte qu'il peut réduire sélectivement le nombre de plaquettes, sans affecter d'autres types de cellules sanguines. Dans la présente invention, tous les intermédiaires clés et les principes pharmaceutiques actifs du chlorhydrate d'anagrélide ont été synthétisés à l'aide de matières premières bon marché et disponibles. A cet égard, des procédés appropriés, pratiques et économiques ont été utilisés en examinant soigneusement les voies de synthèse disponibles pour produire tous les intermédiaires clés et le composant actif d'anagrélide. De plus, les étapes nombreuses et complexes de séparation et de purification de produits ont été grandement facilitées par le développement de procédés simples pour la séparation et la purification de produits, tels que le procédé de cristallisation ou le choix de la combinaison correcte des solvants de lavage.